UBS Downgrades MapLight Therapeutics to Neutral, Lowers Price Target to $13
Benzinga Newsdesk 2 months ago
NewsDowngradesAnalyst RatingsPrice Target
UBS analyst Ashwani Verma downgrades MapLight Therapeutics (NASDAQ:MPLT) from Buy to Neutral and lowers the price target from $52 to $13.
UBS analyst Ashwani Verma downgrades MapLight Therapeutics (NASDAQ:MPLT) from Buy to Neutral and lowers the price target from $52 to $13.